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1. Introduction 
Brain tumor segmentation is an important technique in computer-assisted diagnosis. To 
improve brain tumor diagnosis, it is necessary to use biochemical information provided by 
magnetic resonance spectroscopy (MRS). Some of the challenges involved are determining 
how to combine multimodal signals such as proton MRS and morphological or structural 
images, then knowing how to use the combined information to make a decision. In this 
paper, we propose using a data fusion method to perform an automatic segmentation of the 
brain tumor areas. 
To diagnose brain tissue abnormalities such as tumors, we need to use multispectral 
magnetic resonance images (MRIs), e.g. T1-weighted, T2-weighted, gadolinium, or FLAIR to 
determine some properties of the tumor, including size, position, sort, and relationship with 
other tissues. However, the tumor type and grade are usually diagnosed from 
histopathological examination of a surgical specimen. Proton (1H) magnetic resonance 
spectroscopy (MRS) is a non invasive MR technique that provides biochemical information 
about metabolites. The major biochemical characteristics can provide useful information 
about brain tumor type and grade (Howe et al., 2003a; 2003b). In many studies, the use of in 
vivo 1H-MRS has been described for determining tumor type and grade (Howe et al., 2003a; 
Howe et al., 2003b; Preul et al., 1996; Majós et al., 2009).  
Since analysis of in vivo MRS measurements are dependent on acquisition techniques that 
could compromise the spatial resolution and accuracy of resulting metabolite values 
(Maudsley et al., 2009), metabolic changes associated with disease are frequently small and 
diffuse. Furthermore, using the chemical-shift imaging (CSI) technique, metabolite images, 
known as MR spectroscopic imaging (MRSI) images, can be created using multivoxel MRS 
information, but it is not as visually interpretable as in a structural MRI (Maudsley et al., 
2009). So, for tumor tissue classification, it is important that MRSI be combined with MRI to 
make a more accurate estimation of variations in metabolites, support hypotheses of 
metabolite variation causes, and to yield sufficient information about the tissue.  
For over a decade, scientists have been developing automated brain-tumor classification 
methods using MRS (Garcia-Gomez et al., 2009), but a more clear definition of brain tumor 
type and grade may be obtained by combining MRS or MRSI and MRI (Garcia-Gomez et al., 
2009). A technique used to differentiate glioblastoma from metastatic lesions using MRI and 
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MRS data has been published (Luts et al., 2009). Wang et al. described a classification of 
brain tumors using feature selection and fuzzy connectedness (Wang et al., 2007). These 
features are extracted from MRI and MRS data.  
There are 2 difficulties for combining MRSI data and MRI data. Firstly, these data are 
presented in different modalities, so they do not have the same spatial resolution. There is 
very low spatial resolution per voxel for MRSI, and high spatial resolution per pixel for 
MRI. Secondly, one MR image corresponds to the distribution of many tissues, or many 
tissue structures. But one MRS image is an image which corresponds to 1 metabolite or a 
ratio between several metabolites. So, the different metabolite values cause variation in MRS 
images, as in the mapping of metabolite distributions by MRSI presented in a previous 
study (Maudsley et al., 2009). One of the main questions for application is how to combine 
these MRS images and MR images to give a good automated tissue classification result. The 
key point of the combination is how to model the metabolite distribution from MRS, which 
is coherent with information from MR images.  
For an automated description of a brain tumor type and grade, we propose a modelization 
method of glioma tissues by combining the information from MR images and mulitivoxel 
MRS data. It can create an MRS-weighted MR image automatically, which retains the high 
spatial resolution of an MR image and the grey levels corresponding to biochemical 
abnormalities of pathological processes in brain tissues. The combined data of MRS and T2-
weighted images should be enhanced by an operation of exponential companding. It 
consists of 5 steps: multi-voxel MRS (or CSI) data processing, localization and volume of 
interest (VOI) extraction, data combination, exponential companding, and region growing 
as the last step of segmentation. Data from 2 glioma patients, provided by Tiantan hospital 
in China, have been used to evaluate our method. Two “ground truth”, tumors with edema 
and tumor only, used for result comparison are with manual labels made by 
neuroradiologists at Tiantan and Nanfang hospitals in China. The segmentation result 
represents MRS-weighted T2 structure image in the tumor region. As a performance 
assessment, we obtain 99% correct detection for tumor only and 98% for tumor with 
potential edema, and a false detection rate of 9% and 6% inside VOI, respectively. The 
proposed method is also a simple information fusion strategy. 
2. Quantitative analysis of glial tumor metabolism 
Conventional magnetic resonance imaging (MRI) provides information about tumor 
anatomy, its extent, and pathology; however, the specificity of diagnosis used to distinguish 
between benign and malignant disease and the grade severity is still not optimal. 
Furthermore, MRI does not provide information on the underlying biochemical processes 
associated with tumor progression and potential regression under therapies. Thus, the 
biochemical information from tissues may be useful for specific diagnosis, accurate 
prognosis and follow-up of therapeutic response when used as an adjunct to anatomical 
details obtained from MR images. This can be achieved through in vivo proton Magnetic 
Resonance Spectroscopy (MRS) that provides unique metabolic information, at the 
molecular level, of diagnostic and prognostic importance for tumor typing and grading 
(Galanaud et al., 2007). The tissues contain several biologically important metabolites 
(biochemicals) in addition to water and fat hydrogen atoms that could be followed by MRS. 
It also provides information on the alterations in metabolic pathways during disease 
processes by detection and quantification of metabolites and their temporal variation. MRS 
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is also a useful tool in the planning and evaluation of treatments and in predicting tumor 
progression and treatment response. It is known that tumor growth is not a simple 
regulated phenomenon. There are variations in metabolism and cell density, and in the 
presence of cystic and necrotic regions (particularly in heterogeneous malignant tumors and 
under therapies). Thus, the MR spectrum obtained from tumor tissue can be a mixture of 
different tissue types, including those of different grades, which complicates the spectral 
interpretation. Most MRS measurements are based on the use of proton (1H) nuclei, due to 
its great sensitivity. The integration of 1H MRS with clinical MRI investigation is relatively 
straightforward and easy to implement. Addition of in vivo 1H MRS protocol increases the 
overall acquisition time by approximately 10 to 20 minutes but it drastically improves the 
diagnostic, prognostic accuracy and the follow-up of therapeutic response. This method has 
generated considerable interest in recent years and the added value of the vivo 1H MRS is in 
the process of evaluation in clinical application. In particular it would allow quantification 
of metabolites from a well-defined region of interest (ROI) or volume element (voxel). 
Moreover, the heterogeneous nature of tumors could be understood and detected, which 
would be of great interest for biopsy guidance in time and space (with CSI) and planning, 
monitoring, and evaluation of treatments (Soffietti et al. 2010) such as surgery, radiotherapy, 
and chemotherapy (Hart et al. 2008). Therefore, the possibility of obtaining in vivo 
quantitative biochemical information has revolutionized the field of clinical neurooncology. 
In the present work on gliomas, metabolic information obtained in quantitative single voxel 
MRS measurements, associated with anatomic and perfusion data, allows us to establish an 
accurate prognosis based on a spectral and metabolic classification system and start to 
evaluate therapies. In addition, in longitudinal follow-up studies, multimodality (with 
perfusion and with Positon Emission Tomography (PET) especially in glioblastomas) allow 
us to study the relationship between MRS, MRI segmentation and perfusion, together with 
some biologic parameters (eg, proliferation, infiltration, glycolysis metabolism, necrosis) 
thus helping to characterize sensitive biomarkers and to detect early changes in order to 
assess costly and heavy (for the patient) therapies rapidly and more accurately. Moreover, 
MRS data to be evaluated have to be related to data such as the response to therapy, 
histology, and genetic prognostic mutations (Isocitrate Dehydrogenase 1 IDH1, 1p19q, 
Methyle guanine methyl transferase MGMT).  
Numerous studies reported in the literature have shown that 1H MRS contributes 
significantly to the management of brain tumors. The major metabolites seen at long, 
intermediate, and short echo times are N-Acetyl-aspartate (NAA; 2.02 ppm), total creatine 
(tCr; 3.03 ppm), and choline-containing compounds (tCho; 3.2 ppm). NAA is found 
predominantly in neurons. The tCr level is reduced in astrocytomas and is nearly absent in 
meningiomas and schwannomas, indicating changes in energy metabolism. Gliomatosis 
cerebri is an uncommon and infiltrative type of glioma which is difficult to diagnose but has 
higher levels of tCr, thus distinguishing it from low grade gliomas (Galanaud et al., 2003). 
The tCho/tCr ratio increases with the grade of the glioma (Gill et al., 1990) but the large 
overlap of ratios between grades prevents its individual use as a reliable grading index. The 
level of tCho increases from grade II to grade III in astrocytomas, but grade IV tumors show 
wide variation due to the heterogeneity in cell density and necrosis. It is even more variable 
in gliomatosis. The ratio tCho/NAA was shown to correlate with long-term survival 
independent of tumor type (Nelson et al., 2002). In addition to the above predominant 
metabolites observed at long echo times, additional metabolites such as Glx (glutamate 
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(Glu) and glutamine (Gln), at 3.6-3.9 ppm and 2.1- 2.6 ppm) and myo-inositol (mI, at 3.56 
ppm) are seen at shorter echo times and these also have diagnostic and prognostic potential. 
Lactate (a doublet at 1.33 ppm) is observed in tumors resulting from glycolysis ( Stubbs et 
al., 1995), and lipids (1.3 and 0.9 ppm) are seen in high grade tumors (Howe et al., 2003a; 
Auer et al.,2001; Kuesel et al., 1994).  
For evaluating therapies, one of the purpose is to better understand glial tumor metabolism 
and post chemotherapy, radiotherapy, and antiangiogenic variations. To determine cerebral 
variation in MRS area, amplitude, and ratios of metabolites and spectral profiles during a 6-
year longitudinal follow-up in 26 patients with low grade gliomas (oligodendroglial tumors 
(n=12) or gliomatosis (n=14)) without initial hyperperfusion and treated with Temodal and 
to detect differences in infiltration (NAA), proliferation (Cho/Cr), necrosis (lipids), 
glycolytic metabolism (lactate) or energetic metabolism (glucose and glutamine) at different 
tumoral stages and after therapies. Gliomatosis Cerebri (GC) is a challenging tumor, 
considered to have a poor prognosis and poor response to treatment. 
2.1 Materials, methods and measures  
2.1.1 Patient population  
The World Health Organization (WHO) classification of gliomas is based on the presumed 
cell origin, and distinguishes between astrocytic, oligodendrocytic, and mixed gliomas. A 
grading system is based on the presence of the following criteria: increased cellular density, 
nuclear atypia, mitosis, vascular proliferation, and necrosis. The main histological subtype 
of grade I gliomas is pilocytic astrocytoma, which is benign. Diffuse astrocytomas, 
oligodendrogliomas, and oligoastrocytomas are low grade (II) or high grade (III and IV) 
tumors. Glioblastomas correspond to grade IV astrocytomas.  
We studied glioblastomas and mainly low grade gliomas (oligodendrogliomas and 
gliomatosis). 
2.1.2 MRI acquisition and segmentation  
Measurements of Sagittal T1, axial proton density, T2, FLAIR, diffusion, perfusion, 3D T1 
and 3D T1 planes after gadolinium were acquired (Fig. 1c). Total tumoral volume, volume of 
FLAIR and T2 hypersignal, contrast enhancement, hyperperfusion, and necrosis volumes 
are available on the MRI. A late enhancement should be taken into account. Segmentation 
allows a more quantitative multispectral MRI analysis to estimate tumor volumes, edema 
and necrosis (Fig. 1a and 1b, (Dou et al., 2007a; Dou et al., 2006; Constans, 2006)). These data 
allow us to show that treated tumor volumes, observed on MRI, change little between 2 
measurements, while spectroscopic profiles and Cho/Cr or mI/Cr ratios decrease (see in 
Results of spectroscopy). 
2.1.3 Perfusion  
This NMR technique allows us to study cerebral microcirculation with very fast slice 
acquisition after gadolinium injection (first past perfusion). In glial tumor, the map of 
relative CBV ratio is proportional to area under the curves to evaluate tumoral 
vascularization after intravenous gadolinium injection and showing hyperperfusion.  
The data show some tumoral angiogenesis with severe lesions of the BBB (blood-brain 
barrier). The extravasation of radiocontrast agents induces suceptibility changes, an increase 
in the curve area of first passing above the baseline. Only a few low grade gliomas 
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(gliomatosis and oligodendrogliomas) have shown hyperperfusion (without contrast 
enhancement) at the beginning. Then, more hyperperfusion and small amounts of contrast 
enhancement appear during the progression. 
The relative Cerebral Blood Volume (rCBV) in low grade gliomas is not often elevated, 
between 1 and 3, showing relative hyperperfusion compared to the contralateral side. 
This technique has high temporal resolution and low S/N, and relatively low spatial 
resolution. For this reason, there is interest in the fusion of perfusion data with MRI data 
(T1, gadolinium T1, FLAIR and T2). 
 
  
a) Manual segmentation and tissue classification 
of the different compartments from different 
weighted (T1, T2 and proton density) images 
from an oligodendroglioma that became 
gliomatosis 
b) Segmentation, classification, and fusion of an 
oligodendroglioma that became gliomatosis 
 
 
 
 
 
 
c) Gliomatosis and glioblastoma after segmentation 
Fig. 1. MRI acquisition and segmentation of different types of gliomas,  
2.1.4 MRS Acquisition and data processing 
Single voxels (6 to 12 cm3) from a 1,5 T machine were done on the most aggressive area (Fig. 
2b and 2c) and in the contralateral side (Fig. 2a) using PRESS MRS sequence and with 
multiple TEs (35, 144, 288, 432ms).  
MRS acquisition is sensitive to some parameters and some instrumental problems: 
localization quality, saturation bands, and homogeneity (Constans, 2006). This is even more 
evident in large volumes like CSI. SA/GE software (Fig. 3a) and a home-written SCI-MRS-
LAB (Delcroix, 2000; Chechin, 2001) (Fig. 3b) (at CHU and Caen University and in Scilab 
INRIA-ENPC open source code) automated processing software packages yield amplitudes, 
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areas, ratios, and relative concentrations. Quantification based on amplitude and area 
(proportional to concentration and relaxation) estimation in spectral domain needs solvent 
resonance(s) suppression and presents some difficulties such as unknown resonances and 
molecule metabolization. This process requires normalization with a relative scale with a 
ratio to another metabolite such as water, NAA, Cr, or absolute metabolite concentration 
(absolute scale). 
Data Processing 
There are few quantification methods (SA/GE, JMRUI, SCI-MRS-LAB, THU-MRS0.5 (Dou et 
al., 2009), THU-MRS1.0 (Chi et al., 2011), sparse representation (Guo et al., 2010), which 
include different processing steps, e.g. water suppression, baseline estimation, fitting and 
analysis (Provencher et al., 1982; Nelson, 1989; Nelson, 2001; Hossu, 2009). Fig. 3 shows an 
example of a quantification methods comparison between Vendors such as SAGE 
(Spectroscopy Analysis by General Electric) (Fig. 3a) and SCI-MRS-LAB (Fig. 3b). 
Usually, we can obtain much better water signal suppression and baseline estimation with 
SCI-MRS-LAB than with  SAGE, especially for overlapped coupled spins, eg, glutamate 
and glutamine, citrate, or unusual additional resonance to fit.  
 
 
 
a) Magnetic resonance spectroscopy single voxel short TE 35 ms spectrum from white matter 
contralateral side similar to a normal spectrum 
 
  
b) Example of spectra from gliomatosis tumor onset at 1.5 Tesla in PRESS sequences at different TE: 35 
ms (left) and 144 ms (right) and showing infiltration (NAA/Cr decrease), gliotic activity (slight increase 
of mI and Cr) with some lactate and demyelination compared to onset , 
0 1 2 3 4 
pp
2 3 4 
pp
1 0 
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c) Example of spectral variations in glioma modelized by SCI-MRS-LAB processing software:  
Cho (containing mainly the metabolites glycerophosphocholine (GPC) and elevated phosphocholine 
(PC) at 3.22 ppm): proliferation  
Lactate (at 1.33 ppm): glycolysis  
Decreased NAA/Cr (NAA at 2.02 ppm and Cr at 3.03 ppm): infiltration  
The raw signal is in red, modelization by SCI-MRS-LAB, in green, baseline in green, and residuals in 
blue.In this example, Cho/Cr and mI/ Cr decrease under chemotherapy (Temozolomide [Temodal ®]). 
NAA/Cr ratios are variable and have a tendency to improve under Temozolomide in gliomatosis.  
Fig. 2. MRS acquisition and modelization from a health volintier 2a), and giloma tumors 2b) 
and 2c) 
After therapy, a study of the contralateral side is very important to assess effects of these 
therapies on the remaining non tumoral neuronal tissues. 
Statistical Analysis  
In segmentation, tissular classification, and FLAIR hypersignal extension volume the largest 
variation between n+1 and n exams was retained. Statistical analyses of longitudinal 
spectroscopic data with ztest were done (every 3 months over 60 months).   
The longitudinal evolution of Cr concentration was calculated and, because of its low 
concentration variation in time, this metabolite was used as the reference for the different 
metabolite ratios. Then, Cho/Cr, NAA/Cr, Myoinositol/Creatine (mI/Cr) and Choline/N-
Acetyl-Aspartate (Cho/NAA) were used; their longitudinal variations were studied and 
analysed. 
2.2 Results  
2.2.1 Segmentation  
The segmentation of gliomas is easier to measure than the segmentation of gliomatosis, 
especially when assessing contrast enhancement, necrosis and total volumes. In these 
glioma cases, methods of mathematical morphology or classifications, e.g. Support vector 
machine (SVM) can be used. The segmentation of glioblastomas and oligodendrogliomas is 
also easier than gliomatosis because in this type of glioma with more infiltration, it is 
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difficult to separate the different tumoral compartments and to accurately judge the extent 
of the infiltration, especially when there is little edema and small contrast differences.  
 
 
a) Spectral analysis software from General Electric (SA/GE) 
 
 
b) The raw signal (in red), modelization by SCI-MRS-LAB (in green the signal), base line (in green) and 
residuals (in blue) 
Fig. 3. Example and comparison of SAGE (Figure 3a) and SCI-MRS-LAB (Figure 3b) 
processing for short TE spectra from a normal healthy volunteer, , 
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2.2.2 Spectroscopy results 
Treated (with chemotherapy or radiotherapy) tumoral volumes in MRI, change little (< 20 
%) in low-grade gliomas between 2 exams, while spectroscopic profiles and ratios do change 
(> 60 %) with increases in NAA/Cr and decreases in cho/Cr or mI/Cr ratios, sometimes 
with a tendency to return to more normal values (even in some gliomatosis lesions). 
Without chemotherapy, spectroscopic profiles worsen, with increases in Cho/NAA, Cho/Cr 
and mI/Cr ratios, decreases in NAA/Cr and sometimes with increases in lactate. 
After chemotherapy, treated tumoral volumes in MRI change little between 2 exams, while 
spectroscopic profiles and ratios do change. MRS could, in fact, be more sensitive than MRI 
and could, in some cases, be predictive of worsening.  
2.2.3 Results of longitudinal follow-up  
Some patients with low grade gliomas are still alive 10 years after diagnosis, whereas for 
glioblastoma, we only obtained a few measures because the patients died within 2 years, on 
average. Therefore, we will present longitudinal follow-up studies of low grade gliomas 
(oligodendroglioma and gliomatosis) (Fig. 4). 
Water and creatine are quite stable, which could justify using them for some other ratios to 
quickly detect spectroscopic variations. Cho concentration was predictive in 12 of 26 cases 
and more sensitive than ratios (8/26). Cho concentration increased in 5 patients with 
subsequent aggravation. 
 
 
Fig. 4. Progression with time of a metabolite ratio under treatment: Cho/Cr in 
oligodendroglioma (above) and in gliomatosis (below). 
Cho/Cr seems to decrease more rapidly and more frequently between exams in gliomatosis 
than in oligodendrogliomas. There is sometimes a decrease in the Cho/Cr ratio, but also an 
increase in the mI/Cr ratio (as in Fig 5). 
Concentration of NAA has a tendency to increase with time under Temozolomide, more in 
contralateral, but sometimes in the tumor as well. NAA/Cr ratios are variable and seem to 
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improve with treatment in gliomatosis, but sometimes they show a decrease that precedes 
increased atrophy with FLAIR and T2. Effect of TE on measurements: concentration of NAA 
always shows a higher estimation on the short TE , while lactate shows a higher estimation 
on long TE. 
 
 
Fig. 5. Example of Cho/Cr ratio decrease under Temodal, but increase in mI/Cr ratio. 
2.2.4 Example of perfusion and spectroscopy cases under antiangiogenic therapy  
Later in the progression in 4 patients with hyperperfusion which disappeared with 
antiangiogenic therapy, but proliferation, infiltration, and glycolytic metabolism remained 
at a high level or worsened. (Fig. 6) 
 
 
a) Example of MRI and MRS follow-up of a patient with gliomatosis 
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b) Example of MR Perfusion in another gliomatosis patient with decreased  hyperperfusion that normalizes 
 
 
 
 
 
 
 
 
 
 
 
  
c) Diffusion, FLAIR, contrast enhancement: stability in diffusion and ADC, with FLAIR,  and persistent 
contrast enhancement 
           
d) MRS: Increased proliferation (Cho at 3,22 ppm), glycolytic metabolism (lactate at 1,27-1,33 ppm), and 
infiltration (NAA at 2,02 ppm) at TE 144 and TE 288 ms 
Fig. 6. Patient with good perfusion response to antiangiogenic treatment (Fig. 6b), but with a 
small amount of persistent contrast enhancement (Fig. 6c), intense increased proliferation, 
glycolytic metabolism, and infiltration (Fig. 6d) 
01234
ppm ppm 0 2 1 3 4 
www.intechopen.com
 Diagnostic Techniques and Surgical Management of Brain Tumors 
 
104 
3. Segmentation of brain tumor tissues using information fusion of MRI and 
MRS 
For automated segmentation of brain tumor area, we have proposed a fuzzy information 
fusion based method (Dou, 2006; Dou et al., 2007a; Dou et al., 2007b), using T1-, T2-
weighted and proton-density images. It is a feature fusion system, but it misses important 
biochemical information. The major biochemical characteristics can non invasively provide 
useful information on brain tumor type and grade (Howe et al., 2003b). Therefore, we 
propose a data-fusion strategy to segment brain tumors. This is an exponential companding 
method for enhancing the combination data from T2-weighted image and CSI signal. It 
automatically creates an MRS-weighted T2 structure image, which retains the high spatial 
resolution and brain structure information of the MR image while its grey levels correspond 
to the deterioration of brain tissues. The biochemical information is coherent for 
representing tumor grade and the deterioration of brain tissues. It is the key step in feature 
fusion for creating the feature models of glioma tissues, both for MRS values and for MR 
images. The combination modeling of these 2 types of information should separate the 
glioma tissues and normal tissues. 
3.1 Features in models of glioma tissues 
According to research done on brain tumor diagnosis by MR imaging and MRS, we can 
summarize 2 types of characteristics of glioma: one is the signal intensity of T1-weighted 
(with or without gadolinium) and T2-weighted images, and the other is the chemical-shift 
values of metabolites presented in MRS data. 
3.1.1 Signal intensity characteristics of MR images 
We have proposed some fuzzy modeling methods of different tumoral cerebral tissues on 
MR images based on fusion of tissue features (Dou et al. 2005a; 2005b; Dou, 2006; Dou et al., 
2007a). Table 1 describes the characteristics of brain tissues by creating a gradation of signal 
intensity as a function of different tissues and MRI sequences (Dou et al., 2005a), where CSF 
is cerebral spinal fluid, GM is gray matter, and WM is white matter. In Table 1, the “Seqs” is 
used for “Sequences of MRI”. The symbol “+” represents a hyper-signal; it means that the 
signal intensity is very high and the image is very bright. The symbol “-” represents a hypo-
signal; the intensity is very low and the image is very dark. The symbol “-+” means that the 
signal intensity is higher than hypo-signal, and “+-” means that it is darker than hyper-
signal. “- -” means that the signal intensity is lower than the hypo-signal, and “++” means 
that it is brighter than the hyper-signal. 
Examples of T1-weighted image noted as T1, and T2-weighted image noted as T2 are shown 
in Fig. 7. 
 
Sequences 
Graduality of signal intensity 
CSF GM WM Glioma Edema Necrosis 
T1 ---- - +++ --- --+ ---- 
T2 
+++
+ 
+ -- ++ +++ ++- 
Table 1. Signal intensity characteristics of brain tissues on MR images. 
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                                                      a)                              b) 
Fig. 7. Original MRI images (a) T1 image, (b) T2 image 
3.1.2 Features of metabolite changes in MRS 
Among the large number of metabolites in the human body, there are only some that 
correspond to glioma. These include N-acetyl-asparate (NAA), creatine (Cr), choline (Cho), 
myo-inositol (mI), lactate (Lac), and free lipids (Lip). The variation in these metabolites can 
be ordered in a scalar form, as shown in Table 2, where the scalar order is: absent, very low, 
low, moderately (mod.) low, medium, moderately (mod.) high, high, or very high, which 
correspond to metabolite values from 0 to maximum. The metabolic changes with brain 
tissues are shown in Table 3. Data was obtained from previous studies (Brandao et al., 2003; 
Constans, 2006; Hoa, 2009; Dou et al., 2009).  
 
Metabolite 
level 
absent very 
low
mod. 
low
low medium mod. 
high
high very 
high 
abbreviation A VL LL L M LH H VH 
Table 2. Scalar description of metabolite values 
 
Metabolite variation of metabolites corresponding with brain 
tissues 
CSF GM WM Glioma Edema Necrosis 
NAA VL VH H L/VL M A 
Cho A M LH H/VH LH A 
Cr L H H M/L LL A 
mI L M LH H LH/M A 
Lip A VL L H L VH 
Lac LH VL A VH/H/LH LH H 
Table 3. Metabolite change features in brain tissues on MRS 
The metabolite-ratio characteristics of brain tissues, noted as MetaR and shown in Table 4, 
representing the MetaR characteristics of glioma, edema, and necrosis, are enhanced and the 
normal tissues are reduced. They correspond to signal intensity characteristics of the T2-
weighted image described in Table 1. 
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Metabolite variation of metabolites corresponding with 
brain tissues 
CSF GM WM Glioma Edema Necrosis 
Cho/NAA A VL L VH H A 
Cho/Cr A L L H H A 
mI/Cr M L M H H A 
Lip/Cr A VL VL H M VH 
Lac/Cr LH VL A H H H 
Table 4. Metabolite ratio characteristics of brain tissues 
3.2 Data combination 
There are 2 steps in the stage of data combination. The first, an important operation, is data 
localization, similar to data registration, used to adjust different data into a common 
coordination space. The second step is the actual combination. 
3.2.1 Data localization 
The operation of data localization is used to locate the MRS data to the CSI data, similar to a 
registration process. As their position vectors, recorded in the header of raw data, are under 
the same space coordinate, the volume of interest (VOI) field of MRS could be aligned to the 
image with the help of voxel spacings and position vectors. As shown in Fig. 8, the green 
grid represents the planar position of the voxels of a CSI on its reference image. 
 
 
Fig. 8. An example of data location of MRS and T2 (left), the localization results are shown in 
3D coordinate space (middle and right) 
3.2.2 Data combination 
Data combination is done as a multiplication operation as in (1). The MRS ratio is noted as 
MetaR(i,v), where “i” is the metabolite index and “v” is the voxel index of CSI. The MR image 
is noted as MRIm(p, g), where “p” is the pixel index, and “g” is the grey level of the MR image. 
Normally, MetaR is a function of the voxel determined by the CSI slice shown in Fig. 9. So, it 
is a 2-dimensional function noted as MetaR(i,v). For the same reason, ComIm can be created 
as a 3-dimensional function, noted as ComIm(v, p, g), where “p” is the pixel index 
corresponding to MRIm, and “g” is the grey level of a selected MR image and corresponds to 
“p”. In fact, MRIm is a 2- dimensional function noted as MRIm(p, g), where 
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andgG，  1, 2, , , , , ...T T PD FLAIR Gado Diffusion PerfusionG  
Consider 2 variables: MRIm and ComIm. MRIm is a given image like T2 and ComIm is an 
estimated image. The correlation model MetaR can be considered as some relationship 
between them. So, the regression-like model for estimating GlioIm from MRIm can be 
created as in equation (1). 
 ( , , ) ( , ) ( , )ComIm v p g MetaR i v MRIm p g   (1) 
where “Θ” denotes a necessary operator and “p” corresponds to “v”. If a linear regression is 
necessary, equation (1) can be rewritten as (2): 
 Im( , , ) ( , ) Im( , ) ( , )Glio v p g MetaR i v MR p g MetaR j v     (2) 
where “i” and “j” indicate different metabolites.  
 
(b) original T2 in VOI (c) Cho/Naa in VOI (d) MRS-weighted  
Fig. 9. Example of data combination of MRS and T2-weighted image. (a) is location image of 
CSI with VOI label (white line) on T2. The original image inside the region of VOI is 
enlarged and shown at (b). Two processed MRS resulting from step 1 are shown in the top 
right, corresponding to the voxels of CSI at the position of (1,4) and (3,2) of VOI, 
respectively. MRS ratio in (c) and combined image in (d). 
T2 with localization information of CSI data is shown in Fig. 9 (a). Because MRS is available 
inside a VOI, marked with 6×6 white squares in Fig. 9(a), the combination of T2 and MRS 
should be done inside the VOI. Since the VOI contains multiple image slices, 1 MRS voxel 
corresponds to multi-pixel and multi-slices of an image. 
Two examples of MRS are shown in Fig. 9 on the upper right. The top figure is MRS of a tumor 
voxel with coordinates (1, 4) in the VOI, and the bottom figure is that of normal tissue located 
(a)
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in (3,2) of the VOI. The ratio of Cho/Naa for each voxel is shown in Fig.9(c). The data 
combination of MRS and MR image produces an MRS-weighted image shown in Fig.9 (d). 
3.3 Exponential companding segmentation 
To avoid mosaic effects, we propose a nonlinear regression-like model with spatial 
resolution registration in (3). 
 
( , )
( , , ) exp ( , ) ( . )
MRIm p g
ComIm v p g MetaR i v MetaR j v
T
        (3) 
where “T” is a time constant corresponding to MRIm (p,g). 
According to the correlation model of Table 4, the Lip/Cr and Lac/Cr are specific features w 
dependent on the tumor grade. So, in the model of equation (2), we have:  
 
 
,
/ , / , /
/ , /
i j MetaR
Cho Naa Cho Cr mI Cr
Lip Cr Lac Cr
  


I J I J
I
J
，
 
Because the J of MetaR is the grade marker, it takes an interceptive role to make a different 
grey level from other voxels and indicates a variable grade. 
3.3.1 Example of exponential companding segmentation 
The segmentation method consists of 5 steps:  
Step 1. Processing CSI data to get the relative quantitation of MRS, a ratio of peak 
amplitude or area between 2 metabolites, such as Cho/Naa, as shown in Fig. 9 (c). 
Step 2. Extracting brain from original T2-weighted image, and selecting image slices 
contained in the volume of CSI as shown in Fig.10 (I). 
Step 3. Combining the MRS ratio and the grey level information of selected image slices by 
multiplying the ratio of MRS, e.g. Cho/NAA, to attain MRS-weighted images as 
mentioned in 3.2, and shown in Fig.10 (II).   
Step 4. Exponential companding to extend the difference of grey levels between normal 
tissue and tumor, is done as (2), and shown in Fig.10 (III).   
 ( , , ) exp( ( , , ) / )ExpIm v p g ComIm v p g T    (2)  
where “T” is a time constant corresponding to ComIm and it is determined by the first peak 
of ComIm ‘s histogram.  
Step 5: Tumor area segmentation by region growing, with the brightest pixel selected 
automatically as seed. The results are shown in Fig.10 (IV). 
3.3.2 Material  
The test data consists of CSI raw data and T2-weighted image. These data were acquired 
with STEAM sequence at the Beijing Tiantan hospital (China), with Siemens MR TrioTim 
(3T) and syngo MR B15. The MRS raw data are measured by csi_st/90 protocol with 
TR3000/TE72/TM6. T2-weighted images are measured by t2_tse_tra protocol with 
TR4500/TE80. An example of original test data is shown in the first row of Fig. 7. 
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The resolution of T2 is 0.57×0.57mm2 pixel size and 5mm slice thickness. It can be noted as 
an image voxel of 0.57×0.57×5 mm3. The CSI location image shows that the MRS voxel size 
is 14×14×20mm3. According to the header information of CSI raw data, we can locate 3 
ordinal slices of T2, as shown in Fig. 10(I).  
3.3.3 Segmentation results 
The first step is to process the CSI data to obtain the metabolite ratio. We use THU-MRS1.0, 
a software tool developed by our research group (Dou et al., 2009; Chi et al., 2011) for 
automated processing and quantitative analysis of MRS data, to calculate Cho/Naa voxel-
by-voxel. An example is shown in Fig.9. 
The segmentation result is shown in the fourth row of Fig.10. The output of each step of our 
method can be observed in Fig.10. The first row shows the result from step 2: 3 slices of 
original T2 contained in the volume of CSI. The second row shows the results of step 3: the 
product of the T2 intensity value and the ratio of MRS. The output of step 4, the exponential 
companding result, is shown in the third row.  
 
I 
   
II 
   
III 
 
IV 
   
Fig. 10. Experiment results inside VOI of CSI. The first row shows 3 slices of original T2, 
which are contained in the volume of CSI, and resulting from step 2 of the proposed 
method; the second row presents the results of step 3, the third row resulted from step 4; 
and the last row represents the segmentation result from step 5. 
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3.3.4 Result evaluation 
To evaluate the efficiency of our proposed method, we define the ratio of correct detection 
Pc and false detection Pf as (3) and (4), respectively. 
 100%TruePositivec
RTumor
N
p
N
   (3) 
and  
 100%FalsePositivef
RNormal
N
p
N
   (4) 
where NRNormal is the number of voxels in the region of normal brain tissues, and NRTumor is 
that in the region of tumor tissues, as shown inside the red line in Fig.11. So, the total 
voxel number inside the VOI (white square in Fig.11) is the sum of NRNormal and NRTumor. 
NTruePositive is the number of voxels which are detected as true positives and NFalsePositive is 
that of false positives.  
A true or false positive is related to a standard model, called “ground truth”. In our 
experiment, the ground truth is determined by manual labeling by 2 neuroradiologists, 
shown as a red circle in Fig.11. the first row is the “ground truth” of tumor plus potential 
edema area, called G1, and the second row is that of tumor only, called G2. 
Comparing the segmentation result and the “ground truth”, we obtain the evaluation results 
presented in Table 5. The correct detection rate is 98.89% for tumors with edema, and 99% 
for tumor only. The false detection rate in VOI is 6.48% for tumor with edema and 9.34% for 
tumor only.  
 
 
 
 
Fig. 11. The manual label results with potential edema, G1 (the first row), and without 
edema or tumor only, G2 (the second row). 
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4. Discussion 
MRI remained stable for all patients, except for 2 late partial responses. MRS showed 
variable ratios of mI/Cr, Cho/Cr and NAA/Cr at baseline. We observed a decrease in 
Cho/Cr ratio and mI/Cr (to a lesser extent) and an increase in NAA/Cr ratio for patients 
whose clinical conditions improved and the reverse results for those whose conditions 
deteriorated. 
Chemotherapy, radiation, and antiangiogenic therapies are widely used in the treatment 
of malignant brain tumors (Stupp et al., 2009; Tuettenberg et al., 2006), especially in 
gliomatosis that is inoperable, often leading to a mass effect in the progression, motor or 
language deficits or seizures and and development into high grade gliomas. 
Temozolomide was well tolerated. Patients had initial clinical and MRS improvement and 
stable MRIs. After 18 cycles, MRS showed an increase in the Cho/Cr ratio (proliferation). 
However, later in progression in 4 patients with hyperperfusion, this disappeared but 
proliferation (Cho/Cr), infiltration (NAA), and glycolytic metabolism (lactate) remained 
at a high level. 
The glial tumor segmentation method using data fusion and exponential companding, is 
sensitive to the results of CSI processing and the quantitative analysis of MRS. The area 
ratio of metabolites is widely used in clinics when using single voxel spectroscopy (SVS). 
However, when using CSI data, the partial volume effects will affect neighboring voxels. 
It is then difficult to get a perfect MRS. In our experiment, the amplitude ratio of 
metabolites is better than area ratio because it is not as sensitive to processing results as 
the area ratio.  
We used only one metabolite ratio, Cho/Naa, in our experiment, but for tumor grade 
definition the Lac and Lip are useful. An improved study will focus on CSI processing, data 
combination among other metabolites and other MR images, eg, T1-weighted, FLAIR, and 
gadolinium.  
 
Ground truth Segmentation validation in VOI 
correct detection
Pc (%)
false detection
Pf (%) in VOI
G1 98.89 6.48 
G2 
(tumor only) 
99 9.34 
Table 5. Result evaluation of tumor segmentation in VOI 
5. Conclusion 
The spectroscopic and metabolic changes mentioned here, in addition to improve prognostic 
assessment (Law et al., 2003), occurred well before clinical deterioration and just before 
improvement. MRS allows non invasive follow-up of treated cerebral tumors. Therefore, 
MRS could be more sensitive and could detect changes earlier than MRI and is sometimes 
predictive. 
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There is a large amount of variability, but repetition and modelization of spectroscopic 
measurements during longitudinal follow-up could allow us to diminish it and to 
improve prognostic evaluation, especially in cases being treated with antiangiogenic 
therapy. 
MRI, spectroscopy (MRS), and perfusion could be useful for monitoring energy 
(glutamine and glucose), glycolytic metabolism (lactate), necrosis (lipid metabolism), cell 
proliferation (Cho/Cr), and infiltration (NAA/Cr), and for classifying disease as stable or 
progressive. (Bendszus et al., 2000). These changes, as was shown, can be studied 
longitudinally and non invasively in humans with glial brain tumors after therapies 
(Callot et al., 2008). These repeated measures could give us more insight into the 
evolution at different times of the pathological processes, stages, tumor progression and 
response to therapies. 
It will be important to follow gliomas to see if they become high grade glioma and even 
glioblastoma (Kannuki et al., 1998) in which we can study anatomical FLAIR, metabolism 
and proliferation with parameters from other modalities like MR, PET (11C-MET and 18F-
FLT (Valable et al., 2011) and MRS. Studying the relationship between quantitative MRS 
measures, PET, MRI segmentation, and perfusion parameters could lead to a better 
understanding of tumoral pathological processes and therapeutic response, especially with 
regard to chemotherapy and antiangiogenic molecules, and in the future, hypoxia 
modulators and antioxidant molecules. These relationships could serve as a priori 
knowledge or constraints to improve fusion between CSI and MRI. 
The segmentation method using data fusion of MRI and MRS is only a simple information 
fusion strategy, but it is effective for image segmentation. There are 2 important steps in this 
method: data combination and exponential companding; here, they act as image 
enhancement. It is a good example of image segmentation using data fusion of multimodal 
signals.  
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